Literature DB >> 20688974

The anticonvulsive drug lamotrigine blocks neuronal {alpha}4{beta}2 nicotinic acetylcholine receptors.

Chao Zheng1, Kechun Yang, Qiang Liu, Meng-Ya Wang, Jianxin Shen, A Sofía Vallés, Ronald J Lukas, Francisco J Barrantes, Jie Wu.   

Abstract

Lamotrigine (LTG), an anticonvulsive drug, is often used for the treatment of a variety of epilepsies. In addition to block of sodium channels, LTG may act on other targets to exert its antiepileptic effect. In the present study, we evaluated the effects of LTG on neuronal nicotinic acetylcholine receptors (nAChRs) using the patch-clamp technique on human α4β2-nAChRs heterologously expressed in the SH-EP1 cell line and on native α4β2-nAChRs in dopaminergic (DA) neurons in rat ventral tegmental area (VTA). In SH-EP1 cells, LTG diminished the peak and steady-state components of the inward α4β2-nAChR-mediated currents. This effect exhibited concentration-, voltage- and use-dependent behavior. Nicotine dose-response curves showed that in the presence of LTG, the nicotine-induced maximal current was reduced, suggesting a noncompetitive inhibition. These findings suggest that LTG inhibits human neuronal α4β2-nAChR function through an open-channel blocking mechanism. LTG-induced inhibition in α4β2-nAChRs was more profound when preceded by a 2-min pretreatment, after which the nicotine-induced current was reduced even without coapplication of LTG, suggesting that LTG is also able to inhibit α4β2-nAChRs without channel activation. In freshly dissociated VTA DA neurons, LTG inhibited α4β2-nAChR-mediated currents but did not affect glutamate- or GABA-induced currents, indicating that LTG selectively inhibits nAChR function. Collectively, our data suggest that the neuronal α4β2-nAChR is likely an important target for mediating the anticonvulsive effect of LTG and the blockade of α4β2-nAChR possibly underlying the mechanism through which LTG effectively controls some types of epilepsy, such as autosomal dominant nocturnal frontal lobe epilepsy or juvenile myoclonic epilepsy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20688974     DOI: 10.1124/jpet.110.171108

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  19 in total

Review 1.  Review of pharmacological treatment in mood disorders and future directions for drug development.

Authors:  Xiaohua Li; Mark A Frye; Richard C Shelton
Journal:  Neuropsychopharmacology       Date:  2011-09-07       Impact factor: 7.853

2.  Nicotinic receptor abnormalities as a biomarker in idiopathic generalized epilepsy.

Authors:  Valentina Garibotto; Michael Wissmeyer; Zoi Giavri; Rachel Goldstein; Yann Seimbille; Margitta Seeck; Osman Ratib; Sven Haller; Fabienne Picard
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-09-29       Impact factor: 9.236

3.  DNA damage and oxidative stress induced by seizures are decreased by anticonvulsant and neuroprotective effects of lobeline, a candidate to treat alcoholism.

Authors:  Liana Dantas da Costa E Silva; Patrícia Pereira; Gabriela Gregory Regner; Fernanda Brião Menezes Boaretto; Cleonice Hoffmann; Pricila Pflüger; Lucas Lima da Silva; Luiza Reinhardt Steffens; Ana Moira Morás; Dinara Jaqueline Moura; Jaqueline Nascimento Picada
Journal:  Metab Brain Dis       Date:  2017-10-14       Impact factor: 3.584

4.  Sleep and violence.

Authors:  Maria Livia Fantini; Monica Puligheddu; Alessandro Cicolin
Journal:  Curr Treat Options Neurol       Date:  2012-10       Impact factor: 3.598

Review 5.  Lamotrigine for acute and chronic pain.

Authors:  Philip J Wiffen; Sheena Derry; R Andrew Moore
Journal:  Cochrane Database Syst Rev       Date:  2011-02-16

6.  Effect of triazine derivatives on neuronal nicotinic receptors.

Authors:  Ana Vázquez-Romero; Manuel Criado; Angel Messeguer; Miquel Vidal-Mosquera; José Mulet; Francisco Sala; Salvador Sala
Journal:  ACS Chem Neurosci       Date:  2014-07-07       Impact factor: 4.418

Review 7.  Antiepileptic drugs for neuropathic pain and fibromyalgia - an overview of Cochrane reviews.

Authors:  Philip J Wiffen; Sheena Derry; R Andrew Moore; Dominic Aldington; Peter Cole; Andrew S C Rice; Michael P T Lunn; Katri Hamunen; Maija Haanpaa; Eija A Kalso
Journal:  Cochrane Database Syst Rev       Date:  2013-11-11

8.  Cytisine Exerts an Anti-Epileptic Effect via α7nAChRs in a Rat Model of Temporal Lobe Epilepsy.

Authors:  Jing-Jun Zheng; Teng-Yue Zhang; Hong-Tao Liu; Ze-Xin Huang; Jing-Mei Teng; Jing-Xian Deng; Jia-Gui Zhong; Xu Qian; Xin-Wen Sheng; Ji-Qiang Ding; Shu-Qiao He; Xin Zhao; Wei-Dong Ji; De-Feng Qi; Wei Li; Mei Zhang
Journal:  Front Pharmacol       Date:  2021-06-24       Impact factor: 5.810

9.  New developments in the treatment of partial-onset epilepsy.

Authors:  Frank Mc Besag; Philip N Patsalos
Journal:  Neuropsychiatr Dis Treat       Date:  2012-10-17       Impact factor: 2.570

10.  PPAR-alpha agonists as novel antiepileptic drugs: preclinical findings.

Authors:  Monica Puligheddu; Giuliano Pillolla; Miriam Melis; Salvatore Lecca; Francesco Marrosu; Maria Graziella De Montis; Simona Scheggi; Gianfranca Carta; Elisabetta Murru; Sonia Aroni; Anna Lisa Muntoni; Marco Pistis
Journal:  PLoS One       Date:  2013-05-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.